First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment
Covered in this story
What has happened since
- CenterPoint Energy is up 3.3% since this was published, 45 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $CNP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on CenterPoint Energy →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.